Molecular Target Synopsis
Overview
Domains and Structures
Drugs and Clinical Candidates
Druggability
Chemistry
Ligand Efficiency Plot
Pathways
Family Cladogram
Interaction Network
Gene Expression
Gene Copy Number Variation
RNAi
Mutations
Germline Genetics

UBE2I (P63279) - Overview - Molecular Target Synopsis

Protein


UBE2I, SUMO-conjugating enzyme UBC9
Enzyme Classification 2.3.2.-
UniProt P63279

Also Known as UBC9_HUMAN, UBE2I, UBC9, UBCE9

Accepts the ubiquitin-like proteins SUMO1, SUMO2, SUMO3, SUMO4 and SUMO1P1/SUMO5 from the UBLE1A-UBLE1B E1 complex and catalyzes their covalent attachment to other proteins with the help of an E3 ligase such as RANBP2, CBX4 and ZNF451. Can catalyze the formation of poly-SUMO chains. Necessary for sumoylation of FOXL2 and KAT5. Essential for nuclear architecture and chromosome segregation. Sumoylates p53/TP53 at 'Lys-386'. Interacts with SETX (PubMed:24105744). Interacts with HIPK1, HIPK2, PPM1J, RASD2 and TCF3 Interacts with NR2C1; the interaction promotes its sumoylation (By similarity). Forms a tight complex with RANGAP1 and RANBP2. Interacts with SIAH1 and PARP. Interacts with various transcription factors such as TFAP2A, TFAP2B, TFAP2C, AR, ETS1 and SOX4. Interacts with RWDD3; the interaction enhances the sumoylation of a number of proteins such as HIF1A and I-kappa-B. Interacts with DNMT1. Interacts with FOXL2. Forms a complex with SENP6 and UBE2I in response to UV irradiation. Interacts with DNM1l (via its GTPase and B domains); the interaction promotes sumoylation of DNM1L, mainly in its B domain. Interacts with PML-RARA oncoprotein (via the coiled-colied domain); the interaction is required for sumoylation of the PML-RARA oncoprotein. Interacts with IPO13. Interacts with NFATC2IP; this inhibits formation of poly-SUMO chains. Interacts with FHIT. Interacts with PRKRA and p53/TP53 (By similarity). Interacts with UHRF2. Interacts with NR3C1 and this interaction is enhanced in the presence of RWDD3. Interacts with MTA1. Interacts with ZNF451. Identified in a complex with SUMO2 and UBE2I, where one ZNF451 interacts with one UBE2I and two SUMO2 chains, one bound to the UBE2I active site and the other to another region of the same UBE2I molecule. Interacts with CPEB3 (By similarity). Interacts with SUMO1P1/SUMO5 (PubMed:27211601).

5FQ2
CRYSTAL STRUCTURE OF HUMAN SUMO E1 UFD DOMAIN IN COMPLEX WITH UBC9 IN A P422 SPACE GROUP.
RCSB/PDB
Inspect Structure
See all 3D Structures for UBE2I

Isoforms / Transcripts (Protein Coding)


Sub-cellular localization


UniProt: UBE2I is active in the following subcellular-locations: cytoplasm, nucleus.
GO terms: UBE2I is active in the following subcellular-locations: cytoplasm, cytosol, dendrite, fibrillar center, nuclear envelope, nucleoplasm, nucleus, PML body, sumoylated E2 ligase complex, synapse, synaptonemal complex, transferase complex.



UniProt
GO terms

Gene Copy Number Variation


In COSMIC - Cell Lines Project UBE2I has gain in 2 cell-lines, loss in 2 cell-lines and no signal in 1001 cell-lines. (see details)

Gene Expression


In NCI60, the highest expressing cell lines are: OVCAR_5, ACHN, COLO205

In Array Express (RNA-seq of 675 commonly used human cancer cell lines), the highest expressing cell lines are: NCI-H810, OCUM-1, NCI-H187

In Array Express (RNA-seq of long poly adenylated RNA and long non poly adenylated RNA from ENCODE cell lines), the highest expressing cell lines are: HSMM, SK-N-SH, NHLF

(see details)

3D Structures


For UBE2I there are:
30 structures (35 chains) solved
7 are solved in complex with at least one small molecule ligand



(see details)
Molecular Target 3D Synopsis

Screening and Chemistry


UBE2I has been screened with 20 compounds (24 bioactivities). (see details)